Welcome to our dedicated page for ARDELYX SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARDELYX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARDELYX's regulatory disclosures and financial reporting.
Ardelyx, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 16, 2026 at 8:30 a.m. Eastern Time. Holders of common stock as of April 22, 2026 can vote online, by phone, mail, or during the live webcast.
Stockholders will vote on electing three Class III directors, an advisory Say‑on‑Pay resolution, how often to hold future Say‑on‑Pay votes, ratification of Ernst & Young LLP as auditor for 2026, and an amendment to the 2014 Equity Incentive Award Plan to add 9,000,000 shares. Ardelyx highlights strong governance practices, including an independent chair, fully independent board committees, a classified board structure, and extensive pay‑for‑performance features and clawback, ownership, and anti‑hedging policies.
Ardelyx, Inc. Schedule 13G/A discloses passive institutional holdings by Millennium-related entities and Integrated Core Strategies. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 18,043,970 shares (7.4%) and Integrated Core Strategies (US) LLC reports 17,721,732 shares (7.2%). The filing is a joint filing documented by a April 24, 2026 Joint Filing Agreement.
ARDELYX, INC. filed an initial ownership report for Chief Legal Officer Felecia Ettenberg. The filing shows direct ownership of 237,000 shares of Common Stock.
It also reports a stock option to buy 355,000 shares of Common Stock at an exercise price of $6.30 per share, expiring on April 20, 2036. According to the vesting schedule, 25% of the option vests on April 20, 2027, with the remaining shares vesting in 36 equal monthly installments if her employment continues. Footnotes further note restricted stock units that convert into one share of Common Stock for each unit upon vesting.
ARDELYX, INC. President & CEO Michael Raab exercised stock options and sold shares in a planned transaction. He exercised options for 20,834 shares of common stock at an exercise price of $0.99 per share, then sold 41,668 common shares at a weighted average price of $6.2867 per share pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he holds 1,795,614 shares directly, plus additional indirect holdings of 24,364 and 1,000 shares held in family trusts.
ARDELYX, INC. Chief Medical Officer Dinavahi Rajani reported her equity holdings in connection with a Form 3 filing. She holds stock options to purchase 301,000 shares of Common Stock at an exercise price of $6.11 per share, expiring on April 1, 2036.
She also directly holds 201,000 shares of Common Stock. The option grant vests over time, with 25% of the shares vesting on April 1, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to her continued employment or service with the company.
Ardelyx Inc received an amended Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, Vanguard and its subsidiaries/ divisions will report holdings separately. The filing states amount beneficially owned: 0 and percent of class: 0% as of 03/13/2026.
The amendment cites SEC Release No. 34-39538 (January 12, 1998) and explains that certain Vanguard subsidiaries that formerly were reported under The Vanguard Group, Inc. will now report on a disaggregated basis. The signing official is Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARDELYX, INC. President & CEO Michael Raab exercised stock options to acquire 20,833 shares of common stock at $0.99 per share, then sold 41,666 shares at a weighted average price of $5.84 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, he held 1,816,448 common shares directly and 374,168 stock options of this award, plus indirect holdings of 24,364 and 1,000 shares through family trusts for his children.
ARDELYX, INC. President & CEO Michael Raab reported option exercises and share sales in ARDX. He exercised stock options for 20,833 shares of common stock at an exercise price of $0.99 per share through a derivative conversion. The resulting 20,833 common shares were acquired and then partially offset by an open-market sale of 41,666 common shares at a weighted average price of $6.255 per share, executed in multiple trades between $6.08 and $6.56. The sale was made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, Raab directly held 1,836,153 common shares, with additional shares held indirectly through family trusts for his children.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of common stock tied to exercises and restricted stock units. The notice lists proposed sales of 83,333 shares on 02/24/2026 (exercise of stock options) and 83,333 shares from restricted stock units with a grant date of 02/19/2024. The filing also discloses a sale by Michael G. Raab of 45,982 shares on 02/20/2026 for $268,840.52.
Ardelyx director David M. Mott reported an open-market purchase of 333,333 shares of Ardelyx common stock. The weighted average purchase price was $5.839 per share, with individual trades executed between $5.67 and $6.00 per share. Following this transaction, he reports ownership of 3,302,918 shares, which includes 87,566 shares he holds for the benefit of entities associated with New Enterprise Associates, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.